Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × futibatinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 5 Neoplasms 3 Cholangiocarcinoma 3 Stomach Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Biliary Tract Neoplasms 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Pancreatic Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Leiomyosarcoma 1 Histiocytoma, Malignant Fibrous 1 Head and Neck Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Advanced and Metastatic Urothelial Cancer 1 Adenocarcinoma Of Esophagus 1

Interventions

Doxorubicin 120 Ifosfamide 70 Radiotherapy 65 Cyclophosphamide 61 Gemcitabine 53 Filgrastim 46 Trabectedin 36 pazopanib 34 Docetaxel 34 Etoposide 33 pembrolizumab 32 Vincristine 30 Cisplatin 29 Nivolumab 27 Irinotecan 21 Magnetic Resonance Spectroscopy 20 Carboplatin 20 Ipilimumab 19 Surgical Procedures, Operative 18 Radiation 18 Temozolomide 17 Mesna 16 Melphalan 16 Biopsy 16 Bevacizumab 16 Sirolimus 15 Granulocyte Colony-Stimulating Factor 15 Drug Therapy 15 Dactinomycin 15 Blood Specimen Collection 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03784014 2025-12-11

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Active not recruiting

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡